Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126155211 | 12615521 | 1 | I | 20160728 | 20160802 | 20160802 | EXP | PHHY2016VE105178 | NOVARTIS | 0.00 | M | Y | 0.00000 | 20160802 | MD | VE | VE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126155211 | 12615521 | 1 | PS | TRILEPTAL | OXCARBAZEPINE | 1 | Oral | 5 CM3, TID | 21014 | TID | |||||||||
| 126155211 | 12615521 | 2 | SS | TRILEPTAL | OXCARBAZEPINE | 1 | Oral | 900 MG, QD (STRENGTH: 300 MG) | 21014 | 900 | MG | QD | |||||||
| 126155211 | 12615521 | 3 | SS | TRILEPTAL | OXCARBAZEPINE | 1 | Oral | 900 MG, QD (STRENGTH: 600 MG) | 21014 | 900 | MG | QD | |||||||
| 126155211 | 12615521 | 4 | C | FENOBARBITAL | PHENOBARBITAL | 1 | Unknown | 100 MG, QD | U | 0 | 100 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126155211 | 12615521 | 1 | Seizure |
| 126155211 | 12615521 | 2 | Seizure |
| 126155211 | 12615521 | 4 | Seizure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126155211 | 12615521 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126155211 | 12615521 | Brain oedema | |
| 126155211 | 12615521 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |